Home › Funds › Tetragon Partners GP Ltd › DYN

Tetragon Partners GP Ltd position in DYN

DYNE THERAPEUTICS INC · Health Care

Tetragon Partners GP Ltd reported holding 356,657 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$7.9M, representing 1.29% of its reported portfolio and ranking #17 among its reported holdings. Tetragon Partners GP Ltd has disclosed DYN holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)356.66K sh
Reported value held$7.92M
Portfolio Weight1.29%
First reportedQ2 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tetragon Partners GP Ltd's DYN position evolved

Tetragon Partners GP Ltd first disclosed a stake in DYN in Q2 2025 at 138,375 shares (US$1.3M). The position peaked in Q2 2026 at 356,657 shares, worth US$7.9M. Across 5 filings, Tetragon Partners GP Ltd increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 356,657 shares valued at US$7.9M — an increase of 98,525 shares quarter over quarter.. Notable position changes include a 61% increase in Q3 2025 (shares rose 55% over the following quarter), a 38% increase in Q2 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 138.38K $1.32M New
Q3 2025 223.18K $2.82M Add
Q4 2025 248.00K $4.85M Add
Q1 2026 258.13K $4.68M Add
Q2 2026 356.66K $7.92M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Tetragon Partners GP Ltd held DYN?

Tetragon Partners GP Ltd has disclosed DYN holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Tetragon Partners GP Ltd's current position in DYN?

As of Q2 2026, Tetragon Partners GP Ltd holds 356.66K shares of DYN (DYNE THERAPEUTICS INC), valued at $7.92M, representing 1.29% of its reported portfolio and ranking #17.

Has Tetragon Partners GP Ltd been buying or selling DYN?

In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd increased its position in DYN. The position peaked in Q2 2026 at 356.66K shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.